A New Trend in Drug Development: Leveraging Data from Expanded Access
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Strontium89 (Strontium Chloride Sr-89 injection), a radiopharmaceutical indicated for the relief of bone pain in patients with painful skeletal metastases, has been made available by Q BioMed.
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
The cancer field is not immune to the challenges of out-of-network and surprise billing.
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators.
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system.
Find the right bone cancer treatment regimen with detailed instructions on selection, dosing, and administration of anti-cancer agents such as vincristine.